↓ Skip to main content

Randomized controlled trial of primary prevention of atopy using house dust mite allergen oral immunotherapy in early childhood

Overview of attention for article published in The Journal of Allergy and Clinical Immunology, December 2015
Altmetric Badge
27

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (94th percentile)
  • High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

blogs
1 blog
twitter
27 tweeters
patent
10 patents
facebook
4 Facebook pages
googleplus
2 Google+ users

Citations

dimensions_citation
67 Dimensions

Readers on

mendeley
81 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Randomized controlled trial of primary prevention of atopy using house dust mite allergen oral immunotherapy in early childhood
Published in
The Journal of Allergy and Clinical Immunology, December 2015
DOI 10.1016/j.jaci.2015.04.045
Pubmed ID
Authors

Zaraquiza Zolkipli, Graham Roberts, Victoria Cornelius, Bernie Clayton, Sarah Pearson, Louise Michaelis, Ratko Djukanovic, Ramesh Kurukulaaratchy, S. Hasan Arshad

Abstract

Children born to atopic parents are at increased risk of sensitization to environmental allergens. We sought to demonstrate proof of concept for oral immunotherapy to high-dose house dust mite (HDM) allergen in infancy in the prevention of allergen sensitization and allergic diseases. This was a prospective, randomized, double-blind, placebo-controlled, proof-of-concept study involving 111 infants less than 1 year of age at high risk of atopy (≥2 first-degree relatives with allergic disease) but with negative skin prick test responses to common allergens at randomization. HDM extract (active) and appropriate placebo solution were administered orally twice daily for 12 months, and children were assessed every 3 months. Coprimary outcomes were cumulative sensitization to HDM and sensitization to any common allergen during treatment, whereas development of eczema, wheeze, and food allergy were secondary outcomes. All adverse events were recorded. There was a significant (P = .03) reduction in sensitization to any common allergen (16.0%; 95% CI, 1.7% to 30.4%) in the active (5 [9.4%]) compared with placebo (13 [25.5%]) treatment groups. There was no treatment effect on the coprimary outcome of HDM sensitization and the secondary outcomes of eczema, wheeze, and food allergy. The intervention was well tolerated, with no differences between active and placebo treatments in numbers or nature of adverse events. Prophylactic HDM oral immunotherapy is well tolerated in children at high heredity risk. The results met the trial's prespecified criteria for proof of concept in reducing sensitization to any allergen; however, no significant preventive effect was observed on HDM sensitization or allergy-related symptoms.

Twitter Demographics

The data shown below were collected from the profiles of 27 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 81 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Japan 2 2%
Tunisia 1 1%
Unknown 78 96%

Demographic breakdown

Readers by professional status Count As %
Student > Master 19 23%
Other 10 12%
Student > Bachelor 9 11%
Student > Postgraduate 8 10%
Researcher 8 10%
Other 20 25%
Unknown 7 9%
Readers by discipline Count As %
Medicine and Dentistry 38 47%
Nursing and Health Professions 8 10%
Agricultural and Biological Sciences 7 9%
Social Sciences 4 5%
Psychology 3 4%
Other 8 10%
Unknown 13 16%

Attention Score in Context

This research output has an Altmetric Attention Score of 27. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 January 2020.
All research outputs
#754,840
of 15,380,940 outputs
Outputs from The Journal of Allergy and Clinical Immunology
#749
of 8,634 outputs
Outputs of similar age
#11,670
of 194,774 outputs
Outputs of similar age from The Journal of Allergy and Clinical Immunology
#7
of 69 outputs
Altmetric has tracked 15,380,940 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,634 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.7. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 194,774 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 69 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.